Around July 24–26, 2026, Swiss market-expansion company DKSH signed an agreement to acquire the low-dose oral contraceptive brand Meliane from Bayer, moving the product into DKSH's Healthcare Own Brands portfolio. Terms were not disclosed; the transaction is expected to close by the end of Q3 2026.

Why It Matters

The contraceptive market is quietly restructuring in two directions at once. At the innovation end, venture money is chasing novel mechanisms — Elle MD's copper vaginal ring, Contraline's reversible male implant, Organon's Miudella IUD. At the legacy end, decades-old oral contraceptives are migrating from originator pharma to distributors and specialty holders who can run them profitably at low volume. DKSH buying Meliane is a clean example of the second trend, and it matters for access: whether a 30-year-old pill stays available in 30 markets across North Africa, Asia and the Middle East increasingly depends on whether a distributor thinks the margin works, not on whether a research-driven pharma company still cares. For femtech investors, it's also a reminder that the exit landscape in reproductive health includes trade buyers who want cash-generating brands, not just platform acquirers looking for technology.

Meliane is an old, quiet, durable asset. It has been on the market for more than 30 years and is sold across roughly 30 markets spanning Europe, North Africa, Asia and the Middle East under multiple trade names. Per Femtech Insider, it generated CHF 15 million in net sales in 2025 — a rounding error for Bayer, whose pharmaceutical division runs in the billions, but a meaningful anchor product for a distributor building an owned-brand healthcare business.

DKSH's stated logic is portfolio-building rather than R&D. "The acquisition of Meliane further strengthens our Healthcare Own Brands portfolio and reinforces our commitment to Women's Health as a strategic therapeutic area," said Patrik Grande, Head Business Unit Healthcare at DKSH. "We see significant opportunities to further develop the brand through our market access, distribution and commercialization capabilities." The company already handles commercialization and distribution for women's health products through partnerships with Bayer itself and with period-care brand Enya, so Meliane slots into existing infrastructure.

For Bayer's side of the ledger, this is consistent with a multi-year pattern of large pharmaceutical companies divesting mature contraceptive and women's health assets that no longer justify the internal support they consume — the same dynamic that produced Organon's spinout from Merck, and that recently saw Organon in-license the first new hormone-free IUD in four decades from Sebela. Old contraceptive brands don't die; they get sold to someone whose cost structure suits a CHF 15 million product.

Sources

Update — 2026-08-01

{Initial entry — story first created.}